Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Angel Qin looks at the Chrysalis-2 Trial, which studied the combination of Amivantamab and Lazertinib for EGFR+ NSCLC Patients with Progression on Osimertinib and platinum-based chemo.
We thank our sponsors for this year's support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech
For more, please visit [ Ссылка ].
To join the conversation, visit [ Ссылка ].
Ещё видео!